| Therapeutic
Area |
Product
/ Brand Name |
Indication |
| |
|
|
| Oncology |
Cymevene®
(ganciclovir ) |
For the prevention & treatment of CMV disease in immuno
- compromised individuals & for the prevention of CMV
disease in transplant recipients.
|
| |
Herceptin®
(trastuzumab) |
For the treatment of patients with metastatic breast cancer
who have tumors that overexpress HER 2.
|
| |
MabThera®
(rituximab)
|
The treatment of patients with relapsed or chemoresistant
Indolent B-cell Non Hodgkins Lymphoma and for the treatment
of Aggressive Lymphomas.
|
| |
NeoRecormon®
(epoetin beta) |
Anemia
|
| |
Neupogen®
(filgrastim) |
for decreasing the severity of cytotoxic chemotherapy induced
neutropenia, for the acceleration of myeloid recovery in
patients following autologous or syngeneic bone marrow transplantation,
as adjuvant therapy in ganciclovir (DHPG) - induced
neutropenia in patients with AIDS- related cytomegalovirus
(CMV) retinitis, for the treatment or prophylaxis
of leukopenia associated with myelosuppressive therapies
in patients with bone marrow failure states, treatment
of associated leukopenia.
|
| |
Roferon-A®
(interferon alfa-2a) |
For the treatment of multiple myloma, Kaposi's
sarcoma in AIDS patients with malignant neoplasia, hairy
cell leukemia, chronoic active Hepatitis B & C
|
| |
Xeloda®
(capecitabine) |
The treatment of locally advanced metastatic breast cancer.
First line for metastatic colo-rectal cancer
|
| |
Vesanoid |
Induction of remission in APMC
|
| |
|
Currently distributed in
India by:-
Taksal Pharma Pvt. Ltd.
9-10/3, Asaf Ali Road
Laxman House, Ground Floor
New Delhi 110 002
Tel. +91 11 23240071-74
+91 11 30128001-4
Fax +91 11 23240075
|
